Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

A new trial has found that a weight loss drug taken monthly helps people lose 20 percent of their body weight. Weight loss ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’ - The ...